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Abstract
Background: The molecular chaperone Hsp90 is a promising new target in cancer therapy and selective Hsp90 inhibitors
are currently in clinical trials. Previously these inhibitors have been reported to induce either cell cycle arrest or cell death in
cancer cells. Whether the cell cycle arrest is reversible or irreversible has not generally been assessed. Here we have
examined in detail the cell cycle arrest and cell death responses of human small cell lung cancer cell lines to Hsp90
inhibition.
Methodology/Principal Findings: In MTT assays, small cell lung cancer cells showed a biphasic response to the Hsp90
inhibitors geldanamycin and radicicol, with low concentrations causing proliferation arrest and high concentrations causing
cell death. Assessment of Hsp90 intracellular activity using loss of client protein expression showed that geldanamycin
concentrations that inhibited Hsp90 correlated closely with those causing proliferation arrest but not cell death. The
proliferation arrest induced by low concentrations of geldanamycin was not reversed for a period of over thirty days
following drug removal and showed features of senescence. Rare populations of variant small cell lung cancer cells could be
isolated that had additional genetic alterations and no longer underwent irreversible proliferation arrest in response to
Hsp90 inhibitors.
Conclusions/Significance: We conclude that: (1) Hsp90 inhibition primarily induces premature senescence, rather than cell
death, in small cell lung cancer cells; (2) small cell lung cancer cells can bypass this senescence through further genetic
alterations; (3) Hsp90 inhibitor-induced cell death in small cell lung cancer cells is due to inhibition of a target other than
cytosolic Hsp90. These results have implications with regard to how these inhibitors will behave in clinical trials and for the
design of future inhibitors in this class.
Citation: Restall IJ, Lorimer IAJ (2010) Induction of Premature Senescence by Hsp90 Inhibition in Small Cell Lung Cancer. PLoS ONE 5(6): e11076. doi:10.1371/
journal.pone.0011076
Editor: Mikhail V. Blagosklonny, Roswell Park Cancer Institute, United States of America
Received December 7, 2009; Accepted May 17, 2010; Published June 11, 2010
Copyright:  2010 Restall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants to IL from the Canadian Institutes of Health Research (grant number62797)(http://www.cihr-irsc.gc.ca/e/193.html)
and the Canadian Cancer Society (grant number 020121)(http://www.cancer.ca/canada-wide.aspx?sc_lang=en). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ilorimer@ohri.ca
Introduction
Hsp90 functions as a chaperone in normal cells, promoting the
correct folding of both newly synthesized proteins and proteins
that have been partially denatured due to stress [1]. It appears to
be primarily involved in late stages of folding, probably by
recognizing exposed hydrophobic surfaces on partially folded
proteins. The basic mechanism of Hsp90-induced protein folding
involves conformational switching between open and closed
conformations that is regulated by ATP hydrolysis [2]. Rates of
Hsp90 ATP hydrolysis are controlled in turn by its association
with various cochaperones.
Although the number of proteins known to require Hsp90 for
correct folding continues to increase, Hsp90 is clearly selective for
a subset of cellular proteins. These include a number of proteins
with known oncogenic activity, including Her2, Raf1 and Cdk4
[3]. In some cases Hsp90 shows preferential association with the
mutant, oncogenic forms of proteins; this has been shown for both
Src kinase and the EGF receptor [4-6]. Hsp90 also shows an
increased association with cochaperones and higher ATPase
activity in cancer cells, both in vitro and in vivo [7]. For these
reasons there is considerable interest in Hsp90 as a target for
cancer therapy.
Geldanamycin and radicicol are two structurally unrelated
natural products that bind to the ATP binding site of Hsp90,
blocking the conformational cycling that is necessary for its
chaperone activity. These compounds show good selectivity for
Hsp90, although they also bind to the Hsp90 endoplasmic
reticulum paralog Grp94 and the Hsp90 mitochondrial paralog
Trap1 at higher concentrations [8-10]. While these compounds
establish in principle that Hsp90 is a ‘‘druggable’’ target from a
pharmacology perspective, poor solubility and non-specific
toxicities make them unsuitable for use in humans. Derivatized
versions of geldanamycin have been produced that have improved
pharmacological properties, although they still have some of the
limitations of the parent compound [11]. In spite of this, there is
evidence from some trials that Hsp90 inhibition is achievable,
based on biomarker analysis in patient lymphocytes [12,13] and
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activity [15]. Recently novel Hsp90 inhibitors have been
developed that do not have the limitations of previous compounds,
and these are now entering clinical trials [11]. With these advances
in the pharmacology of Hsp90 inhibition, a critical new area of
investigation will be the identification of subsets of cancer patients
that are most likely to benefit from Hsp90 inhibition.
Lung cancer is the largest cause of cancer deaths worldwide.
About 15% of lung cancers are of a subtype known as small cell
lung cancer. This cancer usually presents as metastatic disease and
is usually not treated with surgery. Small cell lung cancer generally
responds very well to radiation and chemotherapy initially, but the
majority of patients relapse with resistant disease and die within
two years [16]. The majority of small cell lung cancers have
neuroendocrine properties and actively secrete polypeptide
hormones [17]. These secreted hormones cause a range of
paraneoplastic syndromes that are common complications of
small cell lung cancer.
Here we have investigated the response of small cell lung cancer
cells to Hsp90 inhibition. A previous study had shown that Hsp90
inhibitors induce cell death in small cell lung cancer cells via
activation of the intrinsic pathway of apoptosis [18]. Our findings
are consistent with this, but we observed that cell death only occurs
at concentrations far higher than those required for inhibition of
cytosolic Hsp90. We observe that treatment of small cell lung
cancer cells with Hsp90 inhibitors at concentrations that are
sufficient to inhibit cytosolic Hsp90 induces premature senescence
rather than cell death.
Results
Response of human small cell lung cancer cell lines to
Hsp90 inhibition
The human small cell lung cancer cell line H69 showed a
biphasic response to treatment with a range of geldanamycin
concentrations (Figure 1A). In a MTT assay, a 48 h exposure of
cells to 0.1 mM geldanamycin decreased viable cell numbers by
approximately 40%. Increasing the concentration of geldanamy-
cin to up to 3 mM did not cause a further decrease in viable cell
numbers. With concentrations of geldanamycin .4 mM, numbers
of viable H69 cells decreased to essentially zero. Radicicol, a
second Hsp90 inhibitor that is structurally unrelated to geldana-
mycin, also gave a biphasic dose response curve with H69 cells,
although with a less distinct plateau phase (Figure 1B). Two other
small cell lung cancer cell lines (H187 and H889) also show a
biphasic response to geldanamycin (Figure 1C and D); however
the U87MG glioblastoma cell line showed only the first phase of
this response (i.e. the phase seen at low geldanamycin concentra-
tions) (Figure 1E).
As the first phase could be potentially due to either inhibition of
cell proliferation or selective killing of a subset of SCLC cells,
further assays were performed to distinguish between these
possibilities. The response of H69 cells to treatment with a range
of geldanamycin concentrations was assayed by cell counts, using
trypan blue exclusion to distinguish live cells from dead cells
(Figure 1F). The live cell counts also showed a biphasic response
when assayed by this method. Total cell counts were similar to live
cell counts in the first phase of the biphasic response curve but
diverged in the second phase. These data show that geldanamycin
primarily induces proliferation arrest in H69 cells at low
concentrations but induces cell death at high concentrations.
The data in Figure 1C, which show MTT assays on H187 cells
treated for different periods of time (12, 36 and 60 h) with
geldanamycin, are consistent with this conclusion, as the first
phase is only evident with longer treatments where there is time for
significant cell proliferation to take place in the control. This also
shows that the cell death at high geldanamycin concentrations
happens relatively rapidly (i.e. in less than 12 h).
Response of H69 cells after withdrawal of Hsp90
inhibition
Proliferation arrest induced by drugs may be reversible or
irreversible (i.e. senescence-like). To distinguish between these
possibilities, H69 cells were treated with different concentrations of
geldanamycin for two days. Drug was then removed and viable
cell counts were monitored. Cell proliferation recovered from
treatment with geldanamycin concentrations of 50 nM or less.
However, after treatment with 100 nM geldanamycin, a popula-
tion of viable cells remained that did not increase over a time
period of greater than thirty days after removal of drug (Figure 2A).
Similar results were obtained with the H187 and H889 small cell
lung cancer cell lines (Figure 2B and Figure S1A) and in H69 cells
treated with the clinically-relevant Hsp90 inhibitor 17-AAG
(Figure 2C). H69 cells required a minimum of 24 h of exposure
to geldanamycin to induce irreversible proliferation arrest
(Figure 2D) and the induction of irreversible proliferation arrest
was unaffected by caspase inhibition (Figure 2E). For comparison
the same experiment was performed on the U87MG human
glioblastoma cell line (Figure 2F). These cells recover growth after
treatment with 100 nM geldanamycin and also recover from a
treatment with a ten-fold higher concentration of geldanamycin.
The sustained proliferation arrest induced by geldanamycin is
therefore not a universal response of cancer cells but rather is
cancer cell- type specific.
To confirm the sustained growth arrest by a second method,
incorporation of BrdU into H69 cells that had been exposed to
100 nM geldanamycin was also assessed. Consistent with viable
cell counts, this assay showed that H69 cells failed to recover their
proliferative capacity after geldanamycin removal (Figure 3A).
Changes in Hsp90 client proteins and heat shock
proteins in response to Hsp90 inhibition
The effects of different concentrations of geldanamycin on
known Hsp90 clients were also assessed in H69 cells (Figure 3B,
right four lanes of blot). Substantial depletion of the Hsp90 client
proteins Cdk4 and Raf1 were seen at geldanamycin concentra-
tions as low as 50 nM. A second well-described response of cells to
Hsp90 inhibition is the induction of other heat shock proteins that
occurs via activation of Hsf1 [19]. As with client protein responses,
geldanamycin concentrations as low as 50 nM caused increases in
Hsp70, Hsp27 and Hsp90a/b. These geldanamycin concentra-
tions parallel those that cause proliferation arrest, but are about
100 times less than the concentrations that cause substantial cell
death.
U87MG and H69 cells showed very similar sensitivities to
geldanamycin with respect to client protein decreases and heat
shock protein increases (Figure 3B). This indicates that the
difference in behavior between H69 and U87MG cells after
removal of geldanamycin is not a consequence of differences in
drug metabolism (e.g. multidrug transporter activity or diaphorase
activity, both of which affect geldanamycin activity [20,21]).
Rather it appears that the different responses of these cells after
withdrawal of geldanamycin are due to differences that are
downstream of Hsp90 inhibition. Western blot analysis confirmed
that H69 cells lacked detectable p53 (Figure 3B), in agreement
with Smith et al., who showed that there is a stop mutation in P53
exon 5 in this cell line [22]. p16Ink4a was present in H69 cells and
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(Figure 3B).
Senescence markers in growth-arrested small cell lung
cancer cells
The irreversible proliferation arrest induced by Hsp90 inhibi-
tion in small cell lung cancer cells suggested that these cells had
become senescent. To assess this further, additional markers of
senescence were assessed. Figure 4A shows the morphology of
suspension cultures of untreated H69 cells eight days after
geldanamycin removal. Treated cells show some enlargement
and increased cytoplasmic granularity, characteristic features of
senescent cells. Another common feature of senescent cells is the
presence of senescence-associated heterochromatin foci (SAHF)
[23]. Consistent with senescence induction, inhibition of Hsp90
with geldanamycin led to the formation of SAHF in H69 cells
as demonstrated by DAPI staining (Figure 4B). SAHF were
maintained after removal of geldanamycin, as expected for a
senescence marker and were enriched in histone H3 trimethylated
on lysine 9, consistent with previous studies (Figure S1B) [24].
Activation of a DNA damage response is an important feature of
both replicative and premature senescence that contributes to the
growth arrest phenotype of senescent cells [25]. A central feature
of the DNA damage response is the generation of phosphorylated
histone H2AX (cH2AX) at sites adjacent to DNA damage. Both
geldanamycin and radicicol treatments increased levels of cH2AX
Figure 1. Response of small cell lung cancer cells to Hsp90 inhibition. A, MTT assay of H69 cells treated with geldanamycin for 48 h; B, MTT
assay of H69 cells treated with radicicol for 48 h; C, MTT assay of H187 small cell lung cancer cells with geldanamycin for 12, 36 and 60 h; D, MTT assay
of H889 cells treated with geldanamycin for 48 h; E, MTT assay of U87MG glioblastoma cells treated with geldanamycin for 48 h; F, H69 cells treated
with geldanamycin for 48 h and assayed for viable (#) and total (N) cell counts using a Vi-cell XR cell viability analyzer. Error bars show the mean 6 SE
of three replicates.
doi:10.1371/journal.pone.0011076.g001
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to six days after geldanamycin removal, the longest time point
assessed (Figure 4C). This is consistent with reports that senescent
cells maintain an activated DNA damage response for an extended
period after the induction of senescence [25,26].
Isolation of variant H69 cells that bypass geldanamycin-
induced senescence
While H69 cells maintained a proliferation-arrested state for
more than thirty days after removal of geldanamycin, after
approximately forty days a population of cells did start to
proliferate in one experiment. We have designated this population
as H69/41d cells. H69/41d cells have a distinct morphology:
while H69 cells are non-adherent cells that form ragged
aggregates, the variant cells, while also non-adherent, form tight
spheres reminiscent of those seen with stem cell populations
(Figure 5A). Upon retesting, these cells still underwent prolifera-
tion arrest in response to 100 nM geldanamycin, but were able to
recover proliferative capacity upon removal of drug, similar to
what we observed in glioblastoma cells (Figure 5B). H69/41d cells
were also able to recover proliferative capacity after treatment
with the Hsp90 inhibitor radicicol (Figure 5C). Compared to the
parent H69 cell line, H69/41d cells showed similar responses to
Hsp90 inhibition with respect to proliferation inhibition in the
presence of drug, although cell death tended to occur at slightly
lower concentrations than seen with H69 cells (Figure 5D).
Degradation of client proteins and induction of other heat shock
proteins was also similar in the two cell lines (Figure 6A). As above,
Figure 2. Proliferation after withdrawal of Hsp90 inhibitors. Cells were treated for 48 h with the indicated concentration of inhibitor, which
was then removed. Viable cell counts were then determined at the indicated times after inhibitor removal. A, H69 cells treated with geldanamycin; B,
H187 cells treated with geldanamycin; C, H69 cells treated with 17-AAG. D, H69 cells treated with 100 nM geldanamycin for 4, 12 or 24 h. E, H69 cells
were treated for 48 h with 100 nM geldanamycin in the absence or presence of 100 mM Z-VAD-FMK, a general caspase inhibitor. Z-VAD-FMK
treatment was started 1 h before the addition of geldanamycin. F, U87MG cells treated with geldanamycin.
doi:10.1371/journal.pone.0011076.g002
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populations, and indicates that the differences are due to events
downstream of Hsp90 inhibition that specifically affect whether
cells undergo reversible or irreversible proliferation arrest. SAHF
formation was also impaired in H69/41d cells (Figure 6B). In H69
cells, SAHF were detected maximally in approximately 35% of
cells (Figure 6C). In contrast, geldanamycin treatment only caused
a modest increase in SAHF in H69/41d cells and SAHF were
detected in 4.5% of cells maximally (Figure 6C).
To directly assess the genetic relationship of H69 cells with
H69/41d cells, DNA was isolated from both cell lines and
analyzed using Affymetrix Genome-Wide Human SNP Array 6.0
chips, which contain probes for 900,000 single nucleotide
polymorphism and a similar number of probes to assess copy
number variation. Figure S2 shows karyotypes of the two cell lines
reconstructed from this data (each is compared to an Affymetrix
reference karyotype). H69 cells show extensive chromosomal
aberrations as expected for cancer cells. These losses, gains and
regions of amplification/copy number variation are very similar
between H69 and H69/41d cells, showing unequivocally that they
are clonally related. Some differences were evident between the
two cell lines. These include a 4.8 Mbp deletion on the single copy
of chromosome 2 that contains approximately nineteen genes and
a 9.6 Mbp deletion on one copy of chromosome 11 that contains
approximately 83 genes. There is also a gain of the long arm of
chromosome 3 and a loss of a partial long arm of chromosome 15.
However, the SNP/copy number analysis did not point to a single
defined genetic locus that might explain why H69/41d cells are
able to evade Hsp90 inhibitor-induced senescence. As a second
approach to determine the mechanism by which these cells evade
Hsp90 inhibitor-induced senescence, cells were screened for a
number of proteins that have previously been shown to have
important roles in senescence. p21 (CDKN1A, p21Waf1/Cip1) is
one such protein that is of particular interest as it has been shown
to induce senescence in cancer cells lacking p53 [27]. p21 is
expressed in H69 cells but is undetectable in H69/41d cells
(Figure 6D). Given its known role in the induction and
maintenance of senescence [26], the loss of p21 expression
provides a plausible explanation for the failure of H69/41d cells to
undergo senescence in response to Hsp90 inhibitors.
Discussion
In previous studies, the most commonly described response of
cancer cells to Hsp90 inhibition has been cell cycle arrest. This cell
cycle arrest has generally been assumed to be reversible in nature,
although most studies did not address this directly. Growth arrest
can occur at either the G1/S or G2/M transition [28,29] and is
likely to be a consequence of the Hsp90 dependence of proteins
such as CDK4, cdc2 and polo-like kinase [30-32]. In a subset of
cancer cell types, Hsp90 inhibitors have been shown to induce
apoptosis. These include small cell lung cancer cells and multiple
myeloma cells [18,33].
Aside from transient cell cycle arrest and cell death, a third
cellular fate for cancer cells is senescence. For cancer cells, this is
sometimes referred to as ‘‘premature’’ or ‘‘accelerated’’ cellular
senescence to distinguish it from the replicative senescence that
normal cells undergo upon reaching their Hayflick limit [34,35].
Senescence in cancer has been studied in two contexts: the first of
these is the senescence seen in response to oncogene activation,
where it may play a role in protecting organisms from developing
cancer; the second of these is as a response to cancer therapeutics
[36]. Chemotherapy agents that damage DNA appear to induce
senescence to a much greater extent than agents that target
microtubules [37]. This is more likely to occur with exposure to
lower doses of drug, with higher doses causing apoptosis.
Chemotherapy-induced senescence has been observed both in
cell culture and in animal models [38].
The key, defining features of senescent cells are that they remain
metabolically active but undergo a sustained withdrawal from the
cell cycle that is not reversed by standard mitogenic stimuli. After
transient exposure to low concentrations of geldanamycin, small
cell lung cancer cells remained alive and metabolically active (as
indicated by trypan blue exclusion and MTT assays). However
these cells underwent a proliferation arrest that was sustained for
Figure 3. BrdU incorporation and client protein responses in
Hsp90 inhibitor-treated cells. A. H69 cells were treated for 48 h
with 100 nM geldanamycin. Geldanamycin was then removed. Six or
eight days after drug removal, 25,000 treated cells (GA) per well were
plated in ninety-six well plates along with the same number of
untreated H69 cells for comparison (no GA). Cells were allowed to
uptake BrdU for 16 h and BrdU incorporation was then assayed as
described in Materials and Methods. Results were normalized to the
values for untreated cells. Data shown are the mean 6 SD of six
replicates. B. Cells were treated for 48 h with geldanamycin. Total cell
lysates were then collected and analyzed by Western blotting using
antibodies to the indicated proteins. The bottom panel shows a blot
stained for total protein with amido black prior to antibody incubation.
Equal amounts of DMSO were added to cells for each treatment, except
in the leftmost lane, where DMSO was omitted.
doi:10.1371/journal.pone.0011076.g003
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media containing fetal calf serum, a rich source of mitogens. The
proliferation arrest was evident both from live cell counts and from
BrdU incorporation assays.
In addition to permanent proliferation arrest, additional markers
of senescence have been developed, although none of these is
currently seen as being a definitive marker of the senescent state
[39]. A characteristic set of morphological changes have been
described for senescent cells that include cell enlargement and an
increased granularity of the cytoplasm [40]. These features were
evident in H69 small cell lung cancer cells in which sustained
proliferationarrest had been induced by Hsp90 inhibitors. (They do
not show the flattening described for adherent cells, as the small cell
lung cancer cells used in this study grow in suspension.) SAHF are
another marker that is commonly observed in senescent cells and
that are thought to have a role in maintaining the senescent
phenotype. SAHF were present in small cell lung cancer cells in
which sustained proliferation arrest had been induced by Hsp90
inhibitors. Expression of SAHF was maintained for up to six days
after removal of Hsp90 inhibitor (the longest time point examined)
and the time course for their appearance was similar to previous
studies on the induction of premature senescence by various agents
[41,42]. Activation of the DNA damage response is also commonly
observed in senescence, where it has a role in both the initiation and
maintenance of the senescent phenotype [25,26]. Hsp90 inhibitors
(both geldanamycin and radicicol) activated a DNA damage
response that was maintained after inhibitor removal. This finding
is also consistent with a senescence phenotype and provides a
mechanism by which these inhibitors activate senescence.
DNA damage, either telomeric or non-telomeric, is the most
widely characterized inducer of senescence. As well as being a
marker of senescence, the activation of the DNA damage response
by Hsp90 inhibitors also provides a mechanism by which they
induce senescence in small cell lung cancer cells. Previous studies
have also pointed to a link between Hsp90 and DNA damage:
both telomerase and the Fanconi anemia DNA damage response
pathway are dependent on Hsp90 for their activity [43,44].
Senescence-associated b-galactosidase (SAbgal) has also been
widely used as a senescence marker [35]. SAbgal activity is
detected as a consequence of the expansion of the lysosomal
compartment in senescent cells, but is not required for senescence
induction or maintenance [45]. Small cell lung cancer cells treated
with Hsp90 inhibitors were not positive for SAbgal. Adriamycin
also did not induce SAbgal in small cell lung cancer cells when
used at concentrations that induced this marker in other cancer
cell types. This suggests that SAbgal may not be a useful marker of
senescence in small cell lung cancer. A possible explanation is that
these cells have scant cytoplasm and are specialized secretory cells
that may have a relatively small lysosomal compartment.
Taken together, the above data show that Hsp90 inhibitors
induce a sustained proliferation arrest that has features consistent
with premature senescence. This premature senescence occurred
at concentrations of geldanamycin that correlated closely with the
concentrations required to induce the degradation of well-
established Hsp90 client proteins and to induce the expression of
other heat shock proteins (a widely used marker of Hsp90
inhibition). Premature senescence was also induced by 17-AAG
(tanespimycin; 17-allylamino-17-demethoxygeldanamycin), a gel-
danamycin derivative that has been tested in clinical trials [46].
17-AAG induced senescence at a concentration that is similar to
Figure 4. Senescence markers in Hsp90-inhibitor-treated small
cell lung cancer cells. A. H69 cells were treated with DMSO alone or
100 nM geldanamycin for 48 h. Geldanamycin was then removed. Eight
days later cells were allowed to settle onto poly-L-lysine-coated
coverslips, fixed with paraformaldehyde and photographed under
phase contrast using a 63X objective lens. B. SAHF formation after
treatment of cells with Hsp90 inhibitors. H69 cells were treated with
DMSO or 100 nM geldanamycin for 48 h. Cells were then fixed, stained
with DAPI and examined by fluorescence microscopy. C. H69 cells were
treated with DMSO (control) or 100 nM geldanamycin. DMSO and
geldnamycin were then removed on Day 0. Total cell lysates were
collected on the indicated days after geldanamycin removal and
analyzed for cH2AX and H2AX levels by Western blotting. The graph
shows densitometry for Western blot analyses of three biological
replicates. Data were normalized to the vehicle-treated control cells and
are shown as the mean 6 SE.
doi:10.1371/journal.pone.0011076.g004
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maximum tolerated dose of this compound [12], suggesting that
this response is clinically relevant. Senescence induction by Hsp90
inhibitors requires neither p53 nor Rb, as both of these tumor
suppressors are known to be mutated in the H69 cell line used in
this study.
In some experiments, populations of cells did start to grow after
long term culture of senescent H69 cells. One of these cell
populations, designated H69/41d, was characterized in detail. SNP
and copy number analysis of these cells shows that while they are
clearly derived from H69 cells they have a distinct set of genetic
changes. These cells show similar responses to Hsp90 inhibition as
the parent H69 cells with respect to proliferation inhibition in the
presence of drug and induction of cell death at high geldanamycin
concentrations. However they undergo a reversible, rather than
irreversible proliferation arrest in response to Hsp90 inhibition.
H69/41d cells also show identical responses to the parent cell line
with respect to degradation of Hsp90 client proteins and induction
of other heat shock proteins. Thus this form of ‘‘resistance’’ to
Hsp90 inhibition is clearly distinct from that described in previous
studies, where resistance was due to alterations in drug metabolizing
enzymes and was reflected in a requirement for higher doses to see
cellular effects [47]. The isolation of these cells demonstrates that, in
principle, small cell lung cancer cells with additional genetic
alterations can evade Hsp90-induced premature senescence. p21
(CDKN1A)has previously been shown to be an important regulator
of senescence, a property that appears to be independent of its
inhibitory activity against cyclin-dependent kinases [48]. p21 is
regulated by both p53 and p53-independent mechanisms and can
induce sensescence in cells that lack p53 (as is the case for H69 cells)
[27]. The absence of p21 in H69/41d cells provides a mechanism
by which these cells evade premature senescence in response to
Hsp90 inhibition.
We observed two distinct responses to Hsp90 inhibitors in small
cell lung cancer cells, the first being the premature senescence
described above and the second being cell death, which is seen at
much higher concentrations of Hsp90 inhibitors. The two responses
are temporally distinct, in that cell death is maximal after only 12 h
of exposure to Hsp90 inhibitor, while premature senescence
requires a minimum of 24 h exposure to drug. These two responses
were reflected in a biphasic dose response curve in MTT assays,
whichwasvery distinctwith geldanamycinbutwasmoresubtle with
radicicol (see below). The biphasic response is only evident when a
detailed analysis of the dose effects of Hsp90 inhibitors at low
concentrations is performed and when long treatments with drug
are used, where there is sufficient time for cell proliferation to occur
inuntreatedsamples.The inductionofcelldeaththatweobservedis
consistent with previous observations, where it was shown that
Hsp90 inhibitors activate the intrinsic pathway of apoptosis in small
cell lung cancer cells [18]. However we find that the concentration
of geldanamycin required to induce cell death is approximately 100
times higher than that required to inhibit cytosolic Hsp90, as
Figure 5. Properties of variant H69 cells that recover growth after Hsp90 inhibitor withdrawal. A. Photographs of H69 and H69/41d cells
under phase microscopy, at low (top panels) and high (bottom panels) magnification; B. H69 and H69/41d cells were treated with 100 nM
geldanamycin for 48 h. Geldanamycin was then removed and numbers of viable cells were assessed at the indicated times after drug removal. C. H69
and H69/41d cells were treated with 5 mM radicicol for 48 h. Radicicol was then removed and numbers of viable cells were assessed at the indicated
times after drug removal. D. MTT assay of H69/41d cells treated for 48 h with geldanamycin.
doi:10.1371/journal.pone.0011076.g005
Hsp90 and Premature Senescence
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11076assessed by degradation of Hsp90 client proteins and induction of
heat shock proteins. The cell death seen in small cell lung cancer
cells is therefore due to inhibition of a target other than cytosolic
Hsp90; likely alternate targets include either the endoplasmic
reticulum Hsp90 paralog Grp94 or the mitochondrial Hsp90
paralog Trap1. Geldanamycin binds to purified Grp94 and Trap1
with dissociation constants in the 1-2 mM range [8,10]; the IC50 for
the second phase of the curve in our geldanamycin MTT assays is
approximately 5 mM, consistent with either Grp94 or Trap1 as
alternate targets. The large difference in the affinity of geldanamy-
cin for cytosolic Hsp90 in cancer cells (low nanomolar range) and
either Grp94 or Trap1 may explain why a biphasic dose response is
clearly seen with this compound in MTT assays; for compounds
wheretheaffinities arerelativelyclose,this would not be observed as
readily. In the previous report linking small cell lung cancer cell
apoptosis to inhibition of cytosolic Hsp90, the Grp94 and Trap1
binding affinities of the compounds used were not assessed [18].
Previous work has indicated that inhibition of Trap1 (along with
mitochondrial Hsp90) is cytotoxic to cancer cells [49,50]. Similarly,
inhibition of Grp94 can also induce cell death under some
conditions [51]. Trap1 and Grp94 are therefore candidate alternate
targets for the effects of Hsp90 inhibitors on small cell lung cancer
cells both on the basis of their known affinities for Hsp90 inhibitors
and their established roles in the prevention of cell death.
Our studies support the earlier conclusion that small cell lung
cancer may be a candidate for treatment with Hsp90 inhibitors
[18]. However we find that a senescence-like proliferation arrest is
the primary response of these cells to concentrations of Hsp90
inhibitors that inhibit cytosolic Hsp90. This suggests that disease
stabilization may be a more likely outcome in patients rather than
tumor regression, and that small populations of cancer cells with
additional genetic alterations may be able to escape senescence
induction. If, as our data suggests, the apoptotic effect of Hsp90
inhibitors in small cell lung cancer is due to inhibition of other
Hsp90 family members, such as Grp94 or Trap1, it will be
important to develop new drugs that are optimized for selectivity
and potency for these targets.
Materials and Methods
Chemicals and antibodies
Geldanamycin and radicicol were from Sigma-Aldrich Canada
Ltd. (Oakville, ON, Canada). 17-AAG (17-(Allylamino)-17-
demethoxygeldanamycin) and the caspase inhibitor Z-VAD-
FMK were from Calbiochem (San Diego, CA, USA). MTT
reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide) was from Sigma-Aldrich Canada Ltd. (Oakville, ON,
Canada). Cdk4, p21 and Hsp70 mouse monoclonal antibodies
were from Neomarkers (Fremont, CA, USA). Raf1 rabbit
polyclonal antibody was from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). Hsp90a/b mouse monoclonal and Hsp27
rabbit polyclonal antibodies were from Stressgen (Ann Arbor, MI,
USA). Actin and p16 mouse monoclonal antibodies were from
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada). Antibodies
to cH2AX (phospho-Histone H2A.X (Ser139)) and histone
H2A.X were from Millipore (Billerica, MA, USA). Rabbit
polyclonal antibody to histone H3 tri-methylated K9 was from
Abcam (Cambridge, MA, USA). p53 mouse monoclonal antibody
was from Oncogene Science (Uniondale, NY, USA).
Cell lines
Human H69, H187 and H889 small cell lung cancer cell lines
were from American Type Culture Collection (Manassas, VA,
USA). All cell lines were passaged for less than six months
Figure 6. Client protein degradation and SAHF induction in H69/
41d cells. H69 and H69/41d cells were treated for 48 h with geldanamycin
or DMSO as vehicle control. A. Total cell lysates were collected after 48 h
treatment and analyzed by Western blotting as in Figure 3. B. DMSO-treated
cells were stained for SAHF 2 days after removing the DMSO. Geldanamycin-
treated cells were stained for SAHF 2, 4 and 6 days after drug removal.
Representative fluorescence microscopy images of H69 and H69/41d cell
nuclei, six days after removal of geldanamycin, are shown. C. SAHF in H69
(light gray) and H69/41d cells (dark gray) were counted at the indicated
times after drug removal. Data are expressed as the percent of nuclei that
are SAHF positive. Bars show the mean percentage 6 S E .D .T o t a lc e l l
extracts of untreated H69 and H69/41d cells were analyzed for expression of
p21 protein by Western blotting.
doi:10.1371/journal.pone.0011076.g006
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contamination. Small cell lung cancer cell lines were grown as
suspension cultures in RPMI-1640 medium containing 25 mM
HEPES and L-glutamine (Invitrogen, Carlsbad, CA, USA)
supplemented with 100 units/ml penicillin, 100 mg/ml strepto-
mycin, 1 mM sodium pyruvate and 10% (v/v) fetal bovine serum.
The human U87MG glioblastoma cell line was obtained from Dr.
W. Cavenee (Ludwig Institute for Cancer Research, La Jolla, CA,
USA) and was cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 100 units/ml penicillin, 100 mg/ml
streptomycin, 2 mM glutamine and 10% (v/v) of a 2:1 mixture of
donor bovine serum and fetal bovine serum. All cell lines were
cultured at 37uC and 5% CO2.
Cell counts
Total and viable cell numbers were measured using a Vi-cell
XR cell viability analyzer from Beckman Coulter Canada Inc.
(Mississauga, ON, Canada).
Growth assays
Cells were added to 5 ml of media in T25 tissue culture flasks
and 24 h later were treated with drug or the drug vehicle DMSO
(dimethyl sulfoxide) for the specified time. Cells were pelleted by
centrifugation, media with drug was removed, and cells were
washed with sterile PBS and centrifuged again. Cells were then
added to new flasks with fresh media (day 0). Aliquots were
counted for total and viable cell numbers on the specified days and
fresh media was added to replenish and maintain the total volume
of media in the flask. Cell proliferation was also assessed using the
BrdU Cell Proliferation Assay kit from Calbiochem (San Diego,
CA, USA).
MTT assays
Cells were added to 100 ml media in 96-well tissue culture plates
and 24 h later were treated with drug or the drug vehicle DMSO
for the specified time. 25 ml of MTT reagent was added (5 mg/ml
in sterile PBS) and incubated for 24 h at 37uC and 5% CO2. The
cells were lysed and the formazan product was dissolved for
30 min with 100 ml of lysis detergent (20% SDS (BioShop Canada
Inc., Burlington, ON, Canada) and 40% DMF (VWR Interna-
tional, Mississauga, ON, Canada). The absorbance was measured
at 570 nm using a Dynex MRX microplate reader (Dynex
Technologies, Chantilly, VA, USA).
Western blot analysis
Western blotting was performed as described previously [52].
To ensure equal loading and transfer, blots were stained with
amido black prior to blocking and incubation with primary
antibody.
SAHF staining
H69 cells were centrifuged, washed twice with cold PBS for
5 min, fixed in 4% paraformaldehyde at room temperature for
30 min, and washed twice with PBS for 5 min. Cells were stained
for 4 min with 0.13 mg/ml DAPI (49,6-diamidino-2-phenylindole,
Invitrogen, Carlsbad, CA, USA). Cells were then washed twice
with PBS for 5 min and mounted on slides in 5 ml PBS and 5 mlo f
ProLong Gold mounting medium (Invitrogen, Carlsbad, CA,
USA). Fluorescence microscopy was performed using an AxioSkop
2 MOT microscope with a Zeiss FluoArc mercury lamp and Zeiss
AxioVision release 3.1 software (Carl Zeiss Canada Ltd., Toronto,
ON, Canada). Percentages of cells containing SAHFs were
determined by counting total and SAHF- containing nuclei under
a 100X objective. A minimum of three randomly-chosen fields
containing a minimum total of 100 nuclei were scored indepen-
dently by two reviewers and averaged. For detection of histone H3
trimethylated on lysine 9, H69 cells were allowed to settle onto
cover slips coated with 0.1% poly-L-lysine (Sigma-Aldrich, St.
Louis MO) and fixed with paraformaldehyde as above. Immuno-
fluorescence was then performed as described previously using
anti-histone H3 tri-methylated K9 antibody at a 1:5000 dilution
[5].
Microarray-based DNA analysis
DNA was isolated using the DNeasy Blood and Tissue kit from
Qiagen (Mississauga, ON, Canada). Analysis using Genome-Wide
Human SNP Array 6.0 chips from Affymetrix Inc. (Santa Clara,
CA, USA) was performed at the Centre for Applied Genomics at
the Hospital for Sick Children, Toronto, ON, Canada.
Data analysis was performed using the Genotyping Console
software version 3.0.1 from Affymetrix Inc. (Santa Clara, CA,
USA).
Supporting Information
Figure S1 A. H889 human small lung cancer cells were treated
with 100 nM geldanamycin for 48 h. Viable cell numbers were
determined at the indicated days after geldanamycin removal as
indicated in Figure 2. B. H69 were treated with 100 nM
geldanamycin for 48 h. Four days after removal of the drug, cells
were allowed to settle onto poly-L-lysine-coated coverslips and
fixed with paraformaldehyde. Histone H3 trimethylated on lysine
9 was then detected by immunofluorescence (red) with counter-
staining of nuclei using DAPI (green).
Found at: doi:10.1371/journal.pone.0011076.s001 (1.16 MB TIF)
Figure S2 Karyotypes of H69 and H69/41d cells. DNA was
isolated from H69 and H69/41d cells and analyzed using
Affymetrix Genome-Wide Human SNP Array 6.0 chips. The
labels above each column indicate the chromosomes depicted by
each small panel (e.g. column one has five small panels that show
data for chromosomes one, at the top of the column, through five,
at the bottom). Each small panel shows copy number on a scale of
one to five for H69 cells (in blue) and H69/41d cells (in green) for
one chromosome, displayed using the smoothsignal display option
in Affymetrix Genotyping Console software. Data files are
available from the authors on request.
Found at: doi:10.1371/journal.pone.0011076.s002 (0.66 MB TIF)
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